ClinicalTrials.gg
RecruitingNCT06468202ASPIRINUpdated Oct 27, 2026

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

A Phase 4 interventional study of Aspirin 81 mg and Aspirin 162 mg in Hypertensive Disorders of Pregnancy, Preeclampsia and Gestational Hypertension, sponsored by Ohio State University. Recruiting at 20 sites in United States. Open to female participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Ohio State University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 27, 2026Site recruiting status changed4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10,742
Allocation
Randomized
Ages
14 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.

Planned enrollment
Largest of 52
10,742 · median 235
Started
2024
with 4 others
Phase 4
16 of 52
5 open now
Primary completion
2029-01
later than 17 of 21 live
Registered
43rd of 52
by date

Among the 52 studies testing aspirin in Pre-Eclampsia, this one has the largest planned enrollment, is one of 5 that started in 2024, is one of 16 in phase 4, reaches primary completion later than 17 of the 21 other live ones, and was the 43rd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 14 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing aspirin in Pre-Eclampsia, or all of them as a file.
02

Study summary

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

Read the detailed description

Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) and gestational hypertension (gHTN), occur in \~15% of pregnant individuals, disproportionately affect self-identified non-Hispanic Black individuals (with the understanding that race is a socially defined construct and the inequity is related to social determinants of health), are increasing in frequency, and are associated with short- and long-term maternal and neonatal morbidities and mortality. There are currently no available therapeutics to treat individuals with HDP; thus, developing interventions for the prevention of HDP is of substantial public health significance. The U.S. Preventive Services Task Force (USPSTF) and other professional societies recommend or endorse the use of aspirin for prevention of HDP in individuals at high or moderate risk. However, there is great uncertainty regarding optimal dosing, whether there is heterogeneity of effectiveness of aspirin in reducing the risk of HDP among different populations, and what factors are associated with adherence.

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing HDP, and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits. The trial will achieve the following specific aims:

Specific Aim 1: To compare the frequency of HDP (primary outcome), as well as other important secondary outcomes (gHTN, PE, preterm PE, PE-related adverse outcomes, aspirin-related safety outcomes, and patient-reported outcomes related to maternal health, pregnancy, and childbirth experiences) between the two aspirin treatment arms.

Specific Aim 2: To compare the gestational age at birth and the frequency of adverse perinatal outcomes (preterm birth, perinatal death, small-for-gestational-age birth, neonatal intensive care unit admission, and complications of prematurity), as well as patient-reported outcomes related to maternal-infant bonding between the two aspirin treatment arms.

Specific Aim 3: To use quantitative and qualitative analyses to elucidate facilitators and barriers associated with adherence to aspirin therapy in at-risk individuals during pregnancy in order to facilitate future implementation.

03

Conditions studied

  • Hypertensive Disorders of Pregnancy
  • Preeclampsia
  • Gestational Hypertension

Keywords

  • Hypertensive disorders of pregnancy
  • Aspirin treatment
  • Pregnancy
  • Preeclampsia
04

Who can participate

Ages eligible
14 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. live intrauterine gestation ≤16 6/7 weeks gestational age based on best clinical obstetric estimate,
  2. age 14 years or older and able to provide ,
  3. at least one of the following high-risk criteria: i) any prior pregnancy complicated by preeclampsia ii) current pregnancy complicated by chronic hypertension diagnosed before randomization (ACOG) iii) pre-gestational diabetes (on medication for diabetes prior to pregnancy, or diabetes is diagnosed prior to randomization with of 6.5% or greater or abnormal 3-hour glucose tolerance test) iv) twin gestation (including higher order pregnancy reduced to twins prior to 14 weeks) v) chronic kidney disease vi) disease (e.g., antiphospholipid syndrome, systemic lupus erythematous)
  4. or two or more moderate-risk criteria for HDP (per USPSTF), i) nulliparity (no prior delivery at or after 20 weeks 0 days of gestation) ii) obesity ( ≥30 kg/m2 at time of randomization) iii) age ≥35 years (at time of expected estimated due date) iv) Black race v) low income vi) personal risk factors (previous pregnancy with low birth weight or SGA infant, previous adverse pregnancy outcome [unexplained stillbirth], placental abruption, interval >10 years between pregnancies) vii) Family history of preeclampsia (i.e., mother or sister) viii) In vitro fertilization
  5. patient not currently on aspirin OR patient on aspirin for obstetrical indications (e.g., related to IVF, or HDP) and: i- randomized before 130/7 weeks gestation, or ii- randomized on or after 13 0/7 weeks gestation and started aspirin within 2 weeks prior to randomization (e.g., aspirin started for HDP prevention at 12 0/7 weeks and patient randomized at 13 2/7 weeks).

Exclusion criteria

Exclusion Criteria:

  1. known allergy or to aspirin or any medical condition where aspirin is (e.g., active peptic ulcer disease, nasal polyps, NSAID-induced asthma, active gastrointestinal bleeding, known G6PD deficiency, severe hepatic dysfunction, bleeding disorders, history of bariatric surgery),
  2. current or planned aspirin use in pregnancy for non-obstetrical indication (e.g., prior stroke/prior myocardial infraction),
  3. age \< 14 years,
  4. involuntarily confined or detained,
  5. considered as having a diminished decision-making capacity,
  6. obstetrical ultrasound suspicious for major congenital abnormality, known or suspected fetal aneuploidy, fetal demise, or planned pregnancy termination,
  7. participation in another trial that affects the primary outcome, without prior approval of the PI,
  8. plan to deliver at an outside participating site with inability to obtain medical records,
  9. monoamniotic twin gestation because of the risk of fetal demise and preterm delivery,
  10. participation in this trial in prior pregnancy,
  11. triplet or higher order pregnancy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10,742 participants (estimated)

Study arms

  • Experimental
    81 mg Aspirin

    Treatment A consisting of 81mg of aspirin (1 pill of 81mg \& 1 matching placebo) daily

    Drug: Aspirin 81 mg

  • Experimental
    162 mg Aspirin

    Treatment B consisting of 162mg of aspirin (2 pills, each of 81mg) daily

    Drug: Aspirin 162 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Hypertensive Disorder of Pregnancy (HDP)

    HDP defined as preeclampsia or antepartum gHTN based on ACOG criteria

    Time frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks

Secondary outcomes

  1. Preeclampsia

    preeclampsia based on ACOG criteria

    Time frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks

  2. Preterm preeclampsia

    Preeclampsia per ACOG criteria with delivery \< 37 weeks'

    Time frame: From >20 weeks and ≤ 36 weeks 6 days, up to 17 weeks

  3. Postpartum preeclampsia

    Postpartum preeclampsia per ACOG criteria

    Time frame: From delivery weeks till 6 weeks postpartum; 6 weeks

  4. Gestational hypertension

    Gestational hypertension per ACOG criteria

    Time frame: From >20 weeks until onset of labor, up to 22 weeks

  5. Severe maternal morbidity

    Need for intensive care, maternal admission to a hospital within the first 42 days postpartum for obstetric complications, or blood product transfusion

    Time frame: From randomization up to 6 weeks postpartum, up to 48 weeks

  6. Core preeclampsia outcomes

    Composite and individual maternal outcomes (Mortality, Eclampsia, Stroke, Cortical blindness, Retinal detachment, Pulmonary edema, Acute kidney injury, Liver capsule hematoma, Placental abruption, Postpartum hemorrhage, Elevated liver enzymes, Thrombocytopenia, ICU admission, Mechanical ventilation)

    Time frame: From randomization up to 6 weeks postpartum, up to 48 weeks

  7. Bleeding complications (maternal)

    Antepartum bleeding and Placental abruption

    Time frame: From randomization till delivery up to 36 weeks, up to 36 weeks

  8. Bleeding complications (maternal)

    Postpartum hemorrhage

    Time frame: From delivery till hospital discharge, up to 1 week

  9. Adherence to aspirin

    pill count

    Time frame: From randomization until last day of medication intake, up to 42 weeks

  10. Preterm birth

    Delivery \<37 weeks

    Time frame: At time of delivery

  11. Gestational age at birth

    Gestational age in weeks at time of delivery

    Time frame: At time of delivery

  12. Core offspring/neonatal outcomes

    Composite and individual neonatal outcomes (Stillbirth, SGA, Neonatal mortality, Neonatal seizures, Admission to NICU, Respiratory support)

    Time frame: up to 6 weeks post-delivery

  13. Rate of SGA

    Rate of birthweight \<10th percentile

    Time frame: At time of birth

  14. Bleeding complications (neonatal)

    Any neonatal intraventricular or intracranial hemorrhage

    Time frame: Up to 6 weeks post-delivery

  15. Complications of prematurity and neonatal safety outcomes

    Composite of RDS, Grade III-IV IVH, PVL, Stage 2/3 NEC, BPD, Stage III or higher ROP, or early onset sepsis

    Time frame: Up to 6 weeks post-delivery

07

Study locations

15 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.

Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 21, 2024
StartActual
Oct 18, 2024
Primary completionEst.
Jan 1, 2029
CompletionEst.
Feb 1, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. University of Mississippi is now Active, not recruiting
Show 4 added (4 United States)
  • Ochsner Baptist Medical Center · New Orleans, United States
  • University of South Carolina Greenville · Greenville, United States
  • Austin Maternal Fetal Medicine · Austin, United States
  • Baylor College of Medicine · Houston, United States
Oct 27, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • University of Alabama at Birmingham · Birmingham, United StatesContact added (no phone or email listed)
  • University of Mississippi · Jackson, United StatesContact removed m•••@umc.eduContact removed L•••@umc.eduContact removed (no phone or email listed)
  • Brown University · Providence, United StatesContact added (no phone or email listed)
  • University of Utah · Salt Lake City, United StatesContact T•••@hsc.utah.edu→A•••@hsc.utah.eduContact added (no phone or email listed)
  • Inova HealthSystem · Falls Church, United StatesContact added (no phone or email listed)
  • Medical College of Wisconsin · Milwaukee, United StatesContact added (no phone or email listed)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    4 sites added. University of Mississippi is now Active, not recruiting
    Show 4 added (4 United States)
    • Ochsner Baptist Medical Center · New Orleans, United States
    • University of South Carolina Greenville · Greenville, United States
    • Austin Maternal Fetal Medicine · Austin, United States
    • Baylor College of Medicine · Houston, United States
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • University of Alabama at Birmingham · Birmingham, United StatesContact added (no phone or email listed)
    • University of Mississippi · Jackson, United StatesContact removed m•••@umc.eduContact removed L•••@umc.eduContact removed (no phone or email listed)
    • Brown University · Providence, United StatesContact added (no phone or email listed)
    • University of Utah · Salt Lake City, United StatesContact T•••@hsc.utah.edu→A•••@hsc.utah.eduContact added (no phone or email listed)
    • Inova HealthSystem · Falls Church, United StatesContact added (no phone or email listed)
    • Medical College of Wisconsin · Milwaukee, United StatesContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06468202
Collaborators
Patient-Centered Outcomes Research Institute, Northwestern University, Preeclampsia Foundation
Responsible party
Maged Costantine (MD, MBA, Professor, Ohio State University) — Principal investigator
First posted
Jun 21, 2024
Start date
Oct 18, 2024
Primary completion
Jan 1, 2029 (estimated)
Completion
Feb 1, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Maged Costantine, MD, MBA
Contact
Maged.Costantine@osumc.edu
614-293-2222
Kara Rood, MD
Contact
Kara.Rood@osumc.edu
614-293-8045
Maged Costantine, MD, MBA
principal investigator · Ohio State University
Denise Sholtens, PhD
principal investigator · Northwestern University Data Analysis and Coordinating Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion